U.S. Healthtech Stock News

The United States market has shown robust performance, rising 2.0% over the last week and 23% over the past year, with earnings projected to grow by 19% annually. In such a dynamic environment, identifying small-cap stocks that are potentially undervalued can be an appealing strategy for investors seeking opportunities in various regions.

The United States market has shown robust performance recently, climbing 2.0% in the last seven days and rising 23% over the past year, with earnings forecasted to grow by 19% annually. In this thriving environment, identifying stocks that may be trading below their estimated value can provide opportunities for investors seeking potential growth at a reasonable price.

Over the last 7 days, the United States market has risen by 2.0%, and over the past 12 months, it is up by 23%, with earnings expected to grow significantly in the coming years. For those looking to invest in smaller or newer companies, penny stocks—despite being an older term—can still offer surprising value when they are built on solid financial foundations. In this article, we explore several penny stocks that demonstrate financial strength and potential for long-term growth, offering...

Anyone interested in OneSpan Inc. ( NASDAQ:OSPN ) should probably be aware that the CFO & Treasurer, Jorge A. Martell...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

We wouldn't blame UMB Financial Corporation ( NASDAQ:UMBF ) shareholders if they were a little worried about the fact...

Viewing insider transactions for Equillium, Inc.'s ( NASDAQ:EQ ) over the last year, we see that insiders were net...

Some Argan, Inc. ( NYSE:AGX ) shareholders may be a little concerned to see that the Director, William Griffin...

Insiders who bought US$50.0k worth of Gossamer Bio, Inc. ( NASDAQ:GOSS ) stock in the last year have seen some of their...

Insiders who purchased US$397.5k worth of Alpha Cognition Inc. ( NASDAQ:ACOG ) shares over the past year recouped some...

New Jersey Resources (NJR) drew investor attention after reporting year over year gains in revenue and net profit, along with stronger institutional ownership and supportive technical signals that together highlight a period of reinforced stock momentum. See our latest analysis for New Jersey Resources. At a share price of $55.28, New Jersey Resources has a year to date share price return of 20.23%. Its 1 year total shareholder return of 29.83% and 5 year total shareholder return of 61.60%...

If you are wondering whether Ryman Hospitality Properties stock still offers value at current levels, this article walks through what the numbers are saying about the price you see on screen today. The stock last closed at US$122.35, with returns of 3.1% over 7 days, 12.8% over 30 days, 28.1% year to date, 30.8% over 1 year, 51.1% over 3 years, and 73.6% over 5 years. These figures help frame the context for any discussion of valuation. Recent attention on Ryman Hospitality Properties has...

U.S. economic growth projections near 3%, a healthier labor market, and ongoing investment in infrastructure and technology are reshaping where risk and opportunity sit for industrial-focused stocks. The U.S. Industrial Renaissance screener looks for larger companies tied to manufacturing and infrastructure that may be sensitive to these trends, whether through capital spending, construction activity, or automation and AI buildouts. This article highlights 3 stocks from that screener that...

Fresh commentary on Immatics (NasdaqCM:IMTX) highlights its evolution into a broader PRAME-focused oncology platform with multiple monetization paths, alongside reassurance that existing cash resources are expected to support operations into 2028. See our latest analysis for Immatics. Immatics shares recently traded at US$9.52, with a 1-day share price return of 4.73% and 7-day share price return of 7.33%. Over longer periods, the 30-day share price return is down 10.36% and the year-to-date...

In June 2026, Vir Biotechnology’s Board expanded from seven to eight members and appointed Timothy Coughlin, CPA, as a Class III director and Chair of the Audit Committee, effective June 9, 2026. Coughlin’s audit leadership experience and history guiding biotech companies through regulatory and commercial inflection points could influence how investors view Vir’s governance and execution capabilities. We’ll now examine how adding an experienced audit committee chair like Coughlin may shape...

VisionWave Holdings (VWAV) is in focus after using Eurosatory 2026 in Paris to publicly show its VARAN autonomous unmanned ground vehicle, STRATUM AI management platform, and SDNN AI architecture to the global defense community. See our latest analysis for VisionWave Holdings. Alongside the Eurosatory reveal and new data center joint venture term sheet, VisionWave Holdings has seen short term momentum pick up, with a 7 day share price return of 16.06% and a 30 day return of 9.47%. However,...

Recent defense milestones underscore Virtuix's expanding presence in AI-enabled military training and simulation.

The Fed’s latest meeting left rates steady at 3.5% to 3.75%, but a hint of a possible hike later this year, firmer inflation at 4.2%, and a push toward new data sources have quickly reshaped how investors think about risk and opportunity. For technology and data analytics stocks, the focus on real time information and alternative datasets could matter as much as the rate path itself. This article highlights 3 stocks from a US Technology and Data Analytics Providers screener that appear...

Bristol Myers Squibb (NYSE:BMY) reported positive late-stage clinical trial results for two multiple myeloma candidates. The company announced successful Phase III data for mezigdomide in combination with Kyprolis and dexamethasone. Early data for its CAR T-cell therapy arlocabtagene autoleucel showed a strong response rate with a manageable safety profile. The results were presented at the European Hematology Association Congress 2026. Bristol Myers Squibb is a global biopharmaceutical...

Coach, part of Tapestry (NYSE:TPR), has launched &Coach, a digital luxury content platform co-created with Gen Z. The platform focuses on social first storytelling and participatory campaigns, with younger creators embedded in the process. &Coach is intended to reshape how the Coach brand builds community and relevance with younger luxury consumers. Tapestry, trading at $145.87, sits behind Coach as its flagship brand and is leaning into a content driven approach to connect with younger...

Tariffs, shifting trade rules, and pressure on global supply chains are reshaping how investors think about US manufacturing stocks. Instead of relying on smooth cross-border trade, markets are reassessing companies that produce more at home and can better control their costs and inputs. This article looks at three US Domestic Manufacturing screener stocks that are directly exposed to these trade headlines and may react in different ways as policies evolve. Each stock is assessed on its...

With Kevin Warsh preparing for his first post-meeting press conference and the Federal Reserve keeping rates at 3.6% while inflation sits at 4.2%, many investors are rethinking how much risk they want to carry. Large-cap defensive stocks, often backed by steady dividends and stronger balance sheets, can look relatively appealing when rate cuts seem less likely and market swings pick up. This article highlights 3 stocks from our Large-Cap Defensive Stocks screener that appear positively...

With the Federal Reserve hinting at possible rate hikes in 2026 and inflation holding at 4.2%, value stocks are back in focus for investors who care about price tags as much as potential. Higher-for-longer rates can reward companies with resilient balance sheets and sensible valuations, while putting pressure on those priced for perfection. This article highlights three value stocks from our screener that are closely exposed to the latest Fed and inflation news. It explains why some investors...

Earlier in June 2026, GH Research PLC reported full Phase 2a results for its inhaled Mebufotenin (GH001) in postpartum depression, showing rapid remission in all 10 patients, improved maternal functioning, and a favorable safety profile, with findings published in The Journal of Clinical Psychiatry and highlighted at the upcoming CINP 2026 congress. An additional practical insight from the trial was that drug levels in breast milk supported only a brief interruption of breastfeeding around...